Vanguard Group Inc. Buys 290,307 Shares of Zenas BioPharma, Inc. $ZBIO

Vanguard Group Inc. grew its stake in Zenas BioPharma, Inc. (NASDAQ:ZBIO) by 25.0% in the fourth quarter, according to the company in its most recent filing with the Securities and Exchange Commission (SEC). The fund owned 1,453,065 shares of the company’s stock after acquiring an additional 290,307 shares during the quarter. Vanguard Group Inc.’s holdings in Zenas BioPharma were worth $52,761,000 at the end of the most recent quarter.

Other institutional investors and hedge funds also recently modified their holdings of the company. Quarry LP increased its stake in shares of Zenas BioPharma by 34.5% in the 3rd quarter. Quarry LP now owns 1,134 shares of the company’s stock valued at $25,000 after acquiring an additional 291 shares during the last quarter. Russell Investments Group Ltd. bought a new stake in shares of Zenas BioPharma in the 3rd quarter valued at about $30,000. GF Fund Management CO. LTD. bought a new stake in shares of Zenas BioPharma in the 4th quarter valued at about $38,000. BNP Paribas Financial Markets increased its stake in shares of Zenas BioPharma by 120.0% in the 3rd quarter. BNP Paribas Financial Markets now owns 3,146 shares of the company’s stock valued at $70,000 after acquiring an additional 1,716 shares during the last quarter. Finally, CWM LLC increased its stake in shares of Zenas BioPharma by 48.3% in the 4th quarter. CWM LLC now owns 2,178 shares of the company’s stock valued at $79,000 after acquiring an additional 709 shares during the last quarter.

Wall Street Analyst Weigh In

ZBIO has been the subject of a number of recent analyst reports. Guggenheim upped their price target on Zenas BioPharma from $45.00 to $55.00 and gave the company a “buy” rating in a research note on Monday, March 16th. HC Wainwright reaffirmed a “buy” rating and issued a $44.00 price target on shares of Zenas BioPharma in a research note on Friday. Citigroup reiterated a “buy” rating on shares of Zenas BioPharma in a report on Thursday. Wall Street Zen upgraded Zenas BioPharma from a “strong sell” rating to a “sell” rating in a report on Saturday. Finally, Zacks Research cut Zenas BioPharma from a “hold” rating to a “strong sell” rating in a report on Tuesday, March 17th. Six analysts have rated the stock with a Buy rating, one has issued a Hold rating and two have given a Sell rating to the company. According to MarketBeat.com, Zenas BioPharma presently has an average rating of “Hold” and a consensus price target of $44.29.

Zenas BioPharma Trading Down 3.0%

NASDAQ:ZBIO opened at $18.34 on Friday. Zenas BioPharma, Inc. has a fifty-two week low of $8.91 and a fifty-two week high of $44.60. The company has a debt-to-equity ratio of 1.04, a current ratio of 11.94 and a quick ratio of 5.61. The stock has a market capitalization of $1.16 billion, a PE ratio of -2.17 and a beta of -0.61. The business’s 50-day simple moving average is $21.21 and its 200-day simple moving average is $26.75.

Zenas BioPharma (NASDAQ:ZBIO) last released its quarterly earnings data on Wednesday, May 13th. The company reported ($1.46) earnings per share for the quarter, beating the consensus estimate of ($1.47) by $0.01. During the same period in the prior year, the firm posted ($0.80) EPS. Sell-side analysts expect that Zenas BioPharma, Inc. will post -4.97 earnings per share for the current fiscal year.

Insider Activity

In other news, Director Fairmount Funds Management Llc bought 150,000 shares of the business’s stock in a transaction on Tuesday, March 31st. The shares were purchased at an average price of $20.00 per share, for a total transaction of $3,000,000.00. Following the purchase, the director owned 2,359,025 shares of the company’s stock, valued at approximately $47,180,500. The trade was a 6.79% increase in their position. The purchase was disclosed in a document filed with the Securities & Exchange Commission, which can be accessed through this hyperlink. Also, CEO Leon O. Moulder, Jr. bought 35,000 shares of the business’s stock in a transaction on Wednesday, April 29th. The stock was purchased at an average price of $17.62 per share, for a total transaction of $616,700.00. Following the purchase, the chief executive officer directly owned 1,786,039 shares in the company, valued at approximately $31,470,007.18. This represents a 2.00% increase in their position. Additional details regarding this purchase are available in the official SEC disclosure. Insiders have acquired 213,768 shares of company stock worth $4,137,398 in the last 90 days. Corporate insiders own 22.00% of the company’s stock.

Zenas BioPharma Profile

Zenas BioPharma, Inc is a clinical-stage biotechnology company focused on the discovery and development of novel therapies in oncology and infectious diseases. The company’s proprietary platform integrates structure-guided design, computational modeling and high-throughput screening to address challenging protein-protein interactions. Zenas BioPharma is advancing multiple preclinical and clinical-stage candidates aimed at providing new treatment options where current modalities may be limited by efficacy or safety concerns.

Founded in 2021 and headquartered in Cambridge, Massachusetts, Zenas BioPharma was built to streamline the drug discovery process from target identification through to IND-enabling studies.